TRx0014 in Patients With Mild or Moderate Alzheimer's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The primary objective of the study is to investigate the effects of oral TRx0014 at three doses (30, 60 and 100 mg tid) compared with placebo on cognitive ability in patients with mild or moderate dementia of the Alzheimer type. Cognitive ability will be measured by the Alzheimer\'s Disease Assessment Scale - cognitive subscale (ADAS-cog). The primary evaluation will be made at 24 weeks.
Epistemonikos ID: 77a99b148d7596a718caac4f87c078d782cc1638
First added on: May 04, 2024